Search Prime Grants

UH3HL143192

Cooperative Agreement

Overview

Grant Description
1/2 Sickle cell disease and cardiovascular risk - red cell exchange trial (SCD-CARRE trial).
Awardee
University Of Maryland, Baltimore
Funding Goals
THE DIVISION OF BLOOD DISEASES AND RESOURCES SUPPORTS RESEARCH AND RESEARCH TRAINING ON THE PATHOPHYSIOLOGY, DIAGNOSIS, TREATMENT, AND PREVENTION OF NON-MALIGNANT BLOOD DISEASES, INCLUDING ANEMIAS, SICKLE CELL DISEASE, THALASSEMIA, LEUKOCYTE BIOLOGY, PRE-MALIGNANT PROCESSES SUCH AS MYELODYSPLASIA AND MYELOPROLIFERATIVE DISORDERS, HEMOPHILIA AND OTHER ABNORMALITIES OF HEMOSTASIS AND THROMBOSIS, AND IMMUNE DYSFUNCTION. FUNDING ENCOMPASSES A BROAD SPECTRUM OF HEMATOLOGIC INQUIRY, RANGING FROM STEM CELL BIOLOGY TO MEDICAL MANAGEMENT OF BLOOD DISEASES AND TO ASSURING THE ADEQUACY AND SAFETY OF THE NATION'S BLOOD SUPPLY. PROGRAMS ALSO SUPPORT THE DEVELOPMENT OF NOVEL CELL-BASED THERAPIES TO BRING THE EXPERTISE OF TRANSFUSION MEDICINE AND STEM CELL TECHNOLOGY TO THE REPAIR AND REGENERATION OF HUMAN TISSUES AND ORGANS. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, USE SMALL BUSINESS TO MEET FEDERAL RESEARCH AND DEVELOPMENT NEEDS, FOSTER AND ENCOURAGE PARTICIPATION IN INNOVATION AND ENTREPRENEURSHIP BY SOCIALLY AND ECONOMICALLY DISADVANTAGED PERSONS, AND INCREASE PRIVATE-SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT FUNDING. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE TECHNOLOGICAL INNOVATION, FOSTER TECHNOLOGY TRANSFER THROUGH COOPERATIVE R&D BETWEEN SMALL BUSINESSES AND RESEARCH INSTITUTIONS, AND INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL R&D.
Grant Program (CFDA)
93.837 - Cardiovascular Diseases Research
Awarding / Funding Agency
National Heart Lung and Blood Institute (NHLBI) [HHS - NIH]
Place of Performance
Baltimore, Maryland 21201 United States
Geographic Scope
Single Zip Code
Related Opportunity
Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) - Clinical Trial Required (PAR-18-407)
Analysis Notes
Amendment Since initial award the total obligations have increased 504% from $2,775,824 to $16,771,574.
University Of Maryland, Baltimore was awarded Sickle Cell Disease and Cardiovascular Risk- Red Cell Exchange SCD-CARRE Cooperative Agreement UH3HL143192 worth $16,771,574 from National Heart Lung and Blood Institute in May 2019 with work to be completed primarily in Baltimore Maryland United States. The grant has a duration of 7 years and was awarded through assistance program 93.837 Cardiovascular Diseases Research. The Cooperative Agreement was awarded through grant opportunity Clinical Coordinating Center for Multi-Site Investigator-Initiated Clinical Trials (Collaborative UG3/UH3) - Clinical Trial Required.

Status
(Ongoing)

Last Modified 8/20/25

Period of Performance
5/15/19
Start Date
4/30/26
End Date
90.0% Complete

Funding Split
$16.8M
Federal Obligation
$0.0
Non-Federal Obligation
$16.8M
Total Obligated
100.0% Federal Funding
0.0% Non-Federal Funding

Activity Timeline

Interactive chart of timeline of amendments to UH3HL143192

Subgrant Awards

Disclosed subgrants for UH3HL143192

Transaction History

Modifications to UH3HL143192

Additional Detail

Award ID FAIN
UH3HL143192
SAI Number
UH3HL143192-1467014822
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Public/State Controlled Institution Of Higher Education
Awarding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Funding Office
75NH00 NIH National Heart, Lung, and Blood Institute
Awardee UEI
Z9CRZKD42ZT1
Awardee CAGE
1B0S2
Performance District
MD-07
Senators
Benjamin Cardin
Chris Van Hollen

Budget Funding

Federal Account Budget Subfunction Object Class Total Percentage
National Heart, Lung, and Blood Institute, National Institutes of Health, Health and Human Services (075-0872) Health research and training Grants, subsidies, and contributions (41.0) $9,488,478 100%
Modified: 8/20/25